JPMorgan Downgrades Akebia Therapeutics (AKBA) to Underweight

January 29, 2021 4:42 AM EST Send to a Friend
JPMorgan analyst Eric Joseph downgraded Akebia Therapeutics (NASDAQ: AKBA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login